- Shahram Seyedin-Noor — a serial entrepreneur who is now a VC — has announced Fund II following the success of Fund I (which has seen 2 exits already)
Shahram Seyedin-Noor — a serial entrepreneur who is now a VC — has announced Fund II following the success of Fund I (which has seen 2 exits already). Civilization Ventures had announced the closing of its second fund following the successful investment of Fund I in 2017 where the firm had major portfolio exits with the public listing of gene therapy leader Rocket Pharma and the acquisition of Singular Bio by Invitae — which a publicly-traded company at the forefront of advanced medical genetics.
And Civilization Ventures will use the funding to power the most innovative life science companies in the world at the forefront of genomics/diagnostics, synthetic biology, and digital health/AI.
Before starting the fund, Shahram was co-founder, CEO and later Executive Chairman/CBO of Rgenix, a clinical-stage cancer therapeutics company. And he was CFO/VP of Corporate Development at NextBio, a genomics software company acquired by Illumina in 2013.
KEY QUOTES:
“We’re excited to announce our second fund to help visionary founders achieve their dreams and positively impact society. We’re still in the early stages of the health tech and biology revolutions.”
— Shahram Seyedin-Noor, founder and General Partner of Civilization Ventures
“Shahram is a rare breed among VCs. Not only does he have exemplary insights and instincts on markets, teams, and trends, but he carries the operational experience to guide entrepreneurs on how to drive outsized success.”
— Sean Duffy, co-founder and CEO of Omada Health
“Shahram is incredible at what he does. Not only has he connected me with the best VCs in the Valley, but he also connected me with one of our most important advisors, who has been instrumental in our commercialization. Shahram has a unique ability to invest in the best companies at the earliest stages.”
— Oguzhan Atay (PhD), co-founder and CEO of BillionToOne
